Stock market today (April 10, 2026): Nifty50 opens above 23,...
10 Apr 2026
Fredun Pharmaceuticals Limited has completed the allotment of 40,000 equity shares to its promoter upon conversion of warrants, as announced in a board meeting outcome dated April 09, 2026. The conversion marks the completion of a preferential issue process that began with shareholder approval in October 2025.
Warrant Conversion Details
The Board of Directors allotted 40,000 equity shares of face value ₹10 each to Mrs. Daulat Nariman Medhora, a promoter of the company. The conversion was completed after the warrant holder paid the balance consideration amount of ₹3,75,00,000.
Parameter: Details Allottee Name: Mrs. Daulat Nariman Medhora Category: Promoter Shares Allotted: 40,000 Face Value: ₹10 per share Issue Price: ₹1,250 per share Premium: ₹1,240 per share Balance Amount Paid: ₹3,75,00,000
Transaction Timeline
The warrant conversion process followed a structured timeline beginning with regulatory approvals. The Board of Directors had initially allotted convertible warrants on a preferential basis to promoters on December 29, 2025, pursuant to shareholder approval obtained in an Extra-Ordinary General Meeting held on October 22, 2025.
The warrant holders initially paid ₹312.50 per warrant, representing 25% of the issue price. For the conversion, they paid the remaining ₹937.50 per warrant, constituting 75% of the issue price per warrant, totaling ₹3,75,00,000.
Conversion Summary
Metric: Original Warrants Converted Shares Outstanding Warrants Total Count: 40,000 40,000 NIL Status: Fully Converted Allotted None Remaining
Regulatory Compliance
The allotment was conducted in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and followed the SEBI Master Circular dated January 30, 2026. The equity shares have been allotted in dematerialized form and will rank pari passu with existing equity shares of the company.
The preferential issue was executed under Chapter V of the SEBI ICDR Regulations 2018 and other applicable laws. The board meeting commenced at 05:00 p.m. and concluded at 05:30 p.m. on April 09, 2026, with Managing Director Fredun Nariman Medhora (DIN: 01745348) signing the outcome document. The company has informed BSE Limited about the completion of this warrant conversion process through official communication.
Fredun Pharmaceuticals Limited has filed its quarterly compliance certificate with BSE Limited for the quarter ended March 31, 2026, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company submitted the mandatory documentation on April 6, 2026, ensuring adherence to market regulations.
Regulatory Compliance Filing
The company submitted its certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 to BSE Limited's Listing Department. Managing Director Fredun Nariman Medhora signed the compliance document, which was digitally authenticated on April 6, 2026. The filing included a certificate dated April 1, 2026, from the company's SEBI registered registrar and share transfer agent.
Share Transfer Agent Confirmation
Purva Sharegistry (India) Pvt. Ltd., serving as the company's registrar and share transfer agent, provided the required confirmation certificate. The agent, registered with SEBI under registration number INR000001112 as a Category 1 Registrar, confirmed compliance with all dematerialization procedures during the quarter. Ms. Deepali Gaonkar, Compliance Officer at Purva Sharegistry, signed the confirmation document.
Dematerialization Activity Details
During the quarter from January 1, 2026 to March 31, 2026, the company processed dematerialization of share certificates for two shareholders:
Parameter Certificate 1 Certificate 2 Shareholder Name Nikhl Vora Sheela Vora Certificate Number 0016787 0016786 Shares Dematerialized 500 500 Processing Date February 9, 2026 February 9, 2026 Folio Number 000035 000036
The total dematerialization activity for the quarter involved 1,000 shares across two certificates, both processed on the same date in February 2026.
Regulatory Adherence
The registrar confirmed that all security certificates received for dematerialization were properly verified, mutilated, and cancelled after due verification by the depository participant. The names of the depositories were substituted in the register of members as registered owners within prescribed timelines. This compliance ensures that the dematerialized securities maintain their listing status on stock exchanges where the company's earlier issued securities are traded.
The quarterly filing demonstrates Fredun Pharmaceuticals' commitment to maintaining regulatory compliance and transparent reporting to market authorities and stakeholders.
We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.
Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.
